- Scientists have developed a new blood test with over 90 per cent accuracy for detecting aggressive glioblastomas and monitoring their progression.
- Led by the University of Manchester in collaboration with Danish teams, the test identifies tumours and treatment response using two specific blood proteins.
- The breakthrough offers a less invasive and potentially faster diagnostic alternative to current methods like surgical biopsies and extensive MRI scans.
- The test has shown stable and robust results, even as tumours evolve, and can indicate when treatment is not working or cancer has returned earlier than current methods.
- Clinical trials are underway across UK and international sites, with hopes for the test to be integrated into the NHS within a decade for earlier diagnosis and improved patient outcomes.
IN FULL